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Summarv The cvtoreductive effects of anti-transferrin receptor (anti-TfnR) immunotoxins (ITs) and of nrcin
toxin against tumour micromasses hase been evaluated in a multicellular tumour spheroid (MTS) model. More
than 600 (656) MTSs obtained with human breast carcinoma (MCF7) or rat glioblastoma (9L) cell lines were
treated individuallv With ITs or toxin and the effects induced bv the treatment were measured for each MTS as
volume sariation vs time by applying the Gompertz growth model. Two dose-dependent patterns of MTS
grouwth were observed in MTSs of both cell lines in response to IT or toxin treatment: (1) complete inhibition
of MITS growth ('sterilisation'): and (2) partial complete inhibition ('heterogeneous response'). Within the
range of IT or toxin concentrations resulting in partial inhibition of MITS growth. the sensitivity of treated
MITSs was extremelv heterogeneous (the cvtoreductive effects varVing between 0.1 and 4 logs of cells killed for
a given IT or toxin concentration). Analvsis of the post-treatment regrow-th kinetics indicated that treated
non-sterilised and control MTSs reached the same final limiting volumes. However. the doubling time
estimated for the surViVing cells of treated MCF7 and 9L MTSs ranged between 15 and 50 h. indicatinz that
each MITS had indiVidual growing potential. In conclusion. our results indicate that at substerilising IT
concentrations individual heterogeneity of MTSs may greatly influence the cv-toreductiVe potential of ITs. An
implication of our study is that the efficacy of an IT treatment in eradicatin2 disseminated micrometastases
may not be predictable a priori. The MTS model that we describe in this paper may help in dissecting out
factors limiting the effect of ITs in three-dimensional tumours.
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heterogeneitv
Because of their high cell selectivity and potent cell killing
efficacv immunotoxins (ITs) could be ven useful in eradi-
cating microaggregates of tumour cells escaping conventional
therapies and as an adjuvant treatment for the prevention of
tumour relapse (Vitetta et al.. 1993). The cytoreductive
potential of chemo- or radiotherapeutic agents against
tumour masses has been evaluated in a number of experi-
mental models during the past several years (Vitetta et al..
1993). However. little information is available on the direct
effects of ITs on tumour cell aggregates. in which factors
resulting from the three-dimensional organisation of tumour
cells (e.g. antigen site barrier. heterogeneous target antigen
distribution. elevated interstitial pressure) may contribute to
limit the efficacy of an IT-based immunotherapy (Sutherland.
1988: Weinstein and van Osdol. 1992).
Heterogeneity of tumours at three-dimensional as well as
at a single-cell level represents a serious limitation to the
successful application of antineoplastic agents (Norton. 1985:
Sutherland. 1988: Chignola et al.. 1994a). Thus. a correct
evaluation of the real effectiveness of IT-based therapeutic
regimens should take into account the three-dimensional or-
ganisation of tumours as an element adding to the tumour
heterogeneity observed at single-cell level.
The multicellular tumour spheroid (MTS) model. in which
cells grow in vitro as three-dimensional aggregates. represents
an intermediate level of complexity between cells growing as
in vitro monolayers and solid tumours in experimental
animals. MTSs approximate many characteristics of non-
vascularised micromasses or of intervascular regions of larger
tumours (Sutherland. 1988). The growth kinetics of MTSs
closely parallels that of in vivo tumours and can be described
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by the Gompertz growth equation. w-hich offers a common
method of evaluating the consequences of cytoreductive
treatments of three-dimensional structures in vitro and in viio
(Demicheli et al.. 1989). MTSs have been extensively used for
studies of chemotherapy and radiation therapy (Sutherland.
1988: Rofstad and Sutherland. 1989). Moreover. MTSs are
amenable to investigations on the binding and penetration of
MAb and ITs into three-dimensional masses (Kwok et al..
1988; Chen et al.. 1991: Kikuchi et al.. 1992). Recently. poor
and inhomogeneous penetration of an anti-melanoma IT
within MTSs has been reported (Kikuchi et al.. 1992): this
correlated with a lower activity of the ITs against MTSs than
against cell monolayers. Using a similar approach we found
that the potency of anti-TfnR IT or toxin against MTSs is
greatly influenced by the number of target antigens and by
the strength of the IT toxin-cell interaction (Chignola et al..
1994b). In those studies. however. the sensitivitx to treatment
of individual three-dimensional tumour cell aggregates was
not investigated. In vivo tumour relapse is often due to the
regrowth of micromasses escaping therapy. To establish pat-
terns of response to treatment of single micromasses has
obvious therapeutic implications.
In the present work Awe have aimed at quantitating the
cytoreductive effects of ITs directed against individual three-
dimensional tumour structures by taking advantage of the
MTS experimental model. The cytoreductive effects of
chemotherapeutic agents or ITs on MTSs have been
generally examined using low numbers of individually treated
spheroids or w-ith bulk MITS populations (examples in Twen-
tvman. 1980: Rofstad and Sutherland. 1989: Kikuchi et al..
1992: Chignola et al.. 1994b). To gain insights into the
patterns of response to treatment of individual MTSs. we
therefore set out to analyse the individual growth behaviour
of several hundred MTSs treated with a panel of ITs toxin.
Our results demonstrate that the cytoreductive potential of
ITs may be unpredictably influenced by the individual
biological heterogeneities of tumour spheroids.Hi_ekf."nek ofU resonseo iunM-ahwr Xp R Chignoa etal
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Materials and methods
Immunotoxins
The following ITs were used in this work: (a) transfer-
nn-ncin A chain (Tfn-RTA) and anti-TfnR-RTA (OKT9-
RTA and OX26-RTA), requiring the presence of intracel-
lularly active potentiators (e.g. HSA-Mo) to optimise their
cytotoxic activity (Candiani et al., 1992); (b) Tfn-CRM107, a
diphtheria toxin-based IT which does not require the use of
enhancers and enters the cytosol via a different cell intoxica-
tion pathway (Johnson et al., 1989); (c) ricin toxin, which
binds with low affinity to ubiquitous structures present in
large numbers at the cell surface (Olsnes and Pihl, 1982).
Human iron-saturated transferrin (Tfn) was purchased
from Sigma (St. Louis. MO. USA). Hybridoma cells produc-
ing OKT9 (IgGI. directed against the human TfnR) and
OX26 (IgG2a. recognising the rat TfnR) MAbs were
obtained from the American Type Culture Collection (Rock-
ville, MD. USA) and from the European Collection of
Animal Cell Cultures (Salisbury, UK), and grown as ascites
in Balb,c mice. The MAbs were then purified from ascitic
fluid following described procedures (>95% purity) (Can-
diani et al., 1992). Ligand-toxin and MAb-toxin conjugates
were synthesised and purified according to previously pub-
lished procedures (Candiani et al.. 1992) and will all be
referred to as immunotoxins (ITs) throughout the paper.
The IT Tfn-CRM 107 was kindly supplied by Dr RJ Youle.
NIH (Bethesda, MD. USA). Ricin toxin was purified
(>95% purity) from castor beans according to the method
of Nicholson and Blaustein (1972).
HSA -Mo conjugates
Thioether-based human serum albumin-monensin
(HSA-Mo) conjugates were synthesised as described
previously (Candiani et al.. 1992): the Mo:HSA ratio was
4:1. HSA-Mo concentration is given based on Mo.
Multicellular tumour spheroids
MCF7 (human breast carcinoma) and 9L (rat glioblastoma)
cells were cultured at 37'C in a 5% carbon dioxide atmo-
sphere in RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and antibiotics, and
passaged weekly. Spheroids were obtained by inoculating 106
cells in 20 ml of RPMI-FBS 10% in Petri dishes (Costar.
Cambridge. MA, USA) on a thin layer of agar [10 ml of a
0.75% (w v) solution of agar in RPMI-FBS 10%] following
the method described by Yuhas et al. (1977). Spheroids of
about 200-250 gm diameter (approximately 4000 cells per
spheroid) were harvested with a micropipette and placed in a
Petri dish. Single spheroids were then micropipetted into
individual wells of a 96-well U-bottomed microtitre plate on
a layer of agar (20 g.l) and treated with IT. Only spheroids
showing a diameter of 200-250;Lm at the beginning of the
experiments were used. No necrotic core could be observed
at this initial spheroid dimension.
Treatment A total of 656 MCF7 or 9L spheroids sub-
divided in groups of 10-15 MTSs were individually treated
with different doses of ITs in the presence (RTA-IT) or in the
absence (Tfn-CRM107, ricin) of a 50 nM concentration of the
IT-enhancing agent HSA-Mo. The IT was omitted from the
medium of control mock-treated MTS and replaced with
(PBS)-bovine serum albumin (BSA) 0.2%. After 24 h treat-
ment, the IT-containing medium was replaced by fresh
RPMI-FBS 10% by gentle repeated transfer of individual
spheroids into the wells of a 24-well culture plate (Costar,
2 ml per well); MTSs were then placed into the wells of a
24-well culture plate containing I ml of RPMI-10% FBS on
a layer of I ml of 0.75% (w/v) agar in RPMI-10% FBS.
Spheroids were measured daily using a calibrated ocular
micrometer on an inverted microscope. The time '0 days' in
Figures 1 and 2 corresponds to the time immediately follow-
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Fgre I Growth kinetics of treated and control MTSs. Data
points represent measurements of volume increases vs time of a
single control (0) and of a single treated (0) MTS obtained with
9L cells. Curves represent best fits of experimental data with the
Gompertz growth equation. After a growth delay. the treated
MTS regrew following Gompertzian kinetics. Intercepts of fitted
curves with the v-axis at the time of treatment (O days in the
laboratory time scale) supplied the values of the volume and of
the growth rate of both control (VCTRL ccab) and treated (V,a, xa,b)
MTSs. The values of VCTRL and V, were then used to calculate
the log kill effects induced by the treatment. Extrapolations back-
wards along the Gompertz growth curves at the time (biological
time scale) when the spheroids were theoretically composed of a
single cell (VO) allowed us to calculate the values of the instan-
taneous growth rate a. for each MTS.
ing treatments. The longest spheroid diameter (D) and the
perpendicular diameter (d) were measured. The volume (V)
was calculated according to the formula V = 4 3irr3, where
r = (Dd)' 22 is the mean radius of the spheroid. Of the 656
treated spheroids only 66 (10%) were not available for
growth measurements owing to spontaneous disaggrega-
tion.
Data analysis The growth kinetics of treated and control
mock-treated MTSs was followed for 25-35 days. Individual
growth curves were fitted by the Gompertz growth equa-
tion:
V(t) = V(0)exp(cc (1-exp(- 1t)])
where V(t) is the volume of the spheroid at time t, V(0) is the
initial volume at time 0 days, cx is the instantaneous growth
rate (M bc. see below), and P is the retarding factor. The
best fits were performed using a least-square estimation
algorithm which used the modified Newton-Raphson
method (Demicheli et al.. 1989). The computer output also
yielded the following quantities. whose values were taken to
evaluate the goodness of the non-linear curve fitting accord-
ing to widely accepted criteria (reviewed in Baird, 1974;
Landaw and DiStefano, 1984): the standard error (s.e.) and
generalised Student t-value for each parameter; the multiple
correlation coefficient; variance-covariance matrix; and cor-
relation matrix. Curve fitting was considered acceptable in
99% of analysed MTSs.
In Gompertzian growth kinetics the growth rate cx varies
with time (Lloyd. 1975). We therefore distinguished between
the values of cx as measured in laboratory time scale (acb) or
in biological time scale (aE0). The value ofdab gives the growthH_;qogset o MIS responselo i_m d xmun
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Figure 2 Effects of IT or toxin treatment on MTS growth kinetics. A representative experiment is shown. The different symbols
represent volume measurements for individual MTSs; suitable growth curves were fitted with the Gompertz growth equation.
Control MTSs grew following Gompertzian kinetics (a). At the higher doses of IT or toxin used all the treated MTSs were
sterilised'. i.e. no visible regrowth was observed during the time interval of our assays (b). At lower IT or toxin concentrations a
number of MTSs were stenlised. whereas others regrew after a vanable delay (c and d, 'heterogeneous response').
rate of a spheroid at time 0 days of our measurements; the
value of aO gives the initial growth rate of a spheroid when it
was theoretically composed of a single cell (Figure 1 and
Lloyd, 1975; Demicheli et al., 1989). The parameter ato can be
calculated using the following formula, which is obtainable
from the Gompertz growth equation (Demicheli et al., 1989):
XO = Otlb + P In V(O)
V0
where ao, Fb' P and V(O) are as already defined and VO is the
volume of a single cell (assumed to be 10-6mm3; see also
Demicheli et al., 1989).
The cytoreductive effects of anti-TfnR IT and of ricin
toxin on MTSs could be measured only in those spheroids
which displayed a measurable regrowth curve following a
delay. Experimental data of volume increase vs time were
fitted with the Gompertz growth equation and suitable reg-
rowth curves were extrapolated backwards to the time
immediately after treatment (0 days, see Figure 1). The cor-
responding ordinate was taken as the volume of the spheroid
after a given treatment (Vr,) (Demicheli et al., 1988; Chignola
et al., 1994b). The surviving fraction of cells escaping treat-
ment (F) was then calculated using the formula (Demicheli et
al., 1988):
F= Vt. Vcui
where Vt is the volume of control mock-treated MTSs at
time 0 days (Figure 1). The log kill for each treatment could
then be derived as follows (Demicheli et al., 1988; Chignola
et al., 1994b):
log kill=-log(F)
These calculations were caied out under the following
assumptions (Lloyd, 1975):
1. A Gompertz function can be found for treated and
untreated tumour masses which is valid over the entire
growth period.
2. Cells affected by the treatment are killed within a time
span whose length is negligible (instantaneous killing)
compared with the whole period of the tumour mass
regrowth.
3. After a given treatment a tumour mass regrows
immediately (or at least within a limited time) following
Gompertzian growth matching those of control
tumours.
4. In our calculations we also assumed the first-order cell
kill hypothesis advocated by Skipper et al. (1964) to be
valid.
As will be discussed in the next sections, both the growth
behaviour of MTSs and the IT cell-killing properties satisfy
the above requirements.
In all experiments the standard deviation around the mean
volume of control mock-treated MTSs at time t = 0 days was
S20%. The mean volume of control MTSs observed in each
experiment was taken as the V, and its value was used to
calculate F with the formula described above. Standard
deviation around mean values of the log kill calculated from
the errors in the parameters derived from the Gompertzian
curve fitting was <30%.
Results
Effects ofIT or toxin treatment on spheroidgrowth kinetics
To make clear the principles of our data collection process
and to simplify the description of assays involving a great
number of experimental observations, we will first give a,_ d- ITS itrot responseto inmi in ins
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qualitative account of our results followed by a more
rigorous quantitative analysis.
Qualitative analysis The growth kinetics of treated and con-
trol mock-treated MTS was evaluated. Figure 2 shows a
representative experiment: data are expressed as volume inc-
rease of individual MTSs vs time. Growth curves in Figure 2
represent fitting through data points with the Gompertz
growth equation.
Control MTSs grew following Gompertzian kinetics
(Figure 2a). whereas treated MTSs displayed heterogeneous
growth behaviours depending on the IT concentrations used.
For each treatment. two patterns of altered growth kinetics
were observed at different doses of IT or toxin:
1. At the higher concentrations the growth of MTS was
completely inhibited at least within the time frame of
our assays (see Figure 2bW 'sterilising concentrations').
2. At lower concentrations of IT or toxin used the growth
of treated MTS was unpredictably heterogeneous, some
spheroids being sterilised and others showing regrowth
within variable times (see Figure 2c and d).
The two patterns of response to IT treatment as shown in
Figure 2 were observed for all the ITs assayed and for ricin
toxin on both MCF7 and 9L MTSs. The results are sum-
marised in Figure 3. The bars represent the range of anti-
TfnR IT or toxin concentrations inducing a complete inhibi-
tion (sterilisation) and a partial,complete inhibition
(heterogeneous response) on MTS growth. Tfn-CRM107 was
not investigated with 9L MTS since 9L cells are resistant to
high concentrations of this IT (Chignola et al.. 1994b).
MTSs of MCF7 cells were in general more sensitive to IT
or toxin treatment. The higher sensitivity of MCF7 MTSs to
anti-TfnR IT or ricin toxin reflected the same pattern of
sensitivity of MCF7 and 9L monolayers (Chignola et al..
1994b) and could be ascribed to several factors (internalisa-
tion kinetics, intracellular routing. etc.) which have not been
investigated in this study.
represents a measure of the log kill in a single MTS treated
with the indicated IT or toxin concentrations inducing a
heterogeneous response (see also Figure 3). For any given
treatment the cytoreductive effects were highly
heterogeneous, varying between 0.1 log kill and sterilisation.
The variable response of individual MTSs to treatment was
particularly evident with Tfn-CRM107 and OKT9-RTA on
MCF7 MTSs. when the result of the treatment approached
an 'aHl or nothing' effect (Figure 4).
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Quantitative analysis The cytoreductive effects of anti-TfnR
or ncin toxin on MCF7 and 9L MTSs were measured by
fitting suitable regrowth curves of treated MTSs with the
Gompertz growth equation. Calculations were then carried
out as described in Materials and methods. The log kill
calculated for individual MTSs treated with anti-TfnR IT or
with ricin toxin are shown in Figures 4 and 5 for MCF7 and
9L MTS respectively. Each data point in Figure 4 and 5
Fiure 4 Log kill effects induced by IT or toxin treatment on
MCF7 MTS. The log kill effects following treatment at the
indicated IT or toxin concentrations were measured in MCF7
MTSs. Each data point represents the value of the log kill
calculated for a single MTS; MTSs whose growth was completely
inhibited by the treatment (i.e. sterilised) are reported in the
upper panel.
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Figure 3 Summary of the effects induced by the treatments with
ITs or toxin on MTS growth. The assayed concentrations of IT
or toxins inducing -sterilisation' (U) or heterogeneous response
(0) on spheroid growth of both MCF7 and 9L cells are
shown.
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Fivre 5 Log kill effects induced by IT or toxin treatment on 9L
MTSs. For explanations see the legend to Figure 4.
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Gompertlian growth oftreated and control MTSs
The results in Figure 2 show that treated non-sterilised MTSs
regrew following Gompertzian growth kinetics. However, the
volume vs time profiles in the treated non-sterilised MTS
populations appeared more heterogeneous than that of the
control MTS. In order to compare in a more quantitative
way the Gompertzian growth of treated non-sterilised and
control MTS. we considered the Gompertzian parameters of
each MTS as estimated by fitting of experimental data with
the Gompertz growth equation. In fact. the Gompertz
growth model supplies the two parameters ac0 and P corres-
ponding to the initial growth rate of the tumour (ac0) and to
the so-called 'retarding factor' (p) (see Matenrals and methods
and Demicheli et al.. 1989). It has been reported that the two
parameters ao and i for monolayers. spheroids and xenog-
rafted tumours are linearly correlated (Demicheli et al.. 1989.
1991). Moreover, the ratio cxo i appears to be tumour and
tissue specific and remains constant irrespective of the his-
totype or the 'age' or the size of the tumour (Brunton and
Weldon. 1980; Demicheli. 1980; Demicheli et al., 1989).
Thus, the ratio oco/p is a measure of the distinctive Gompert-
zian growth pattern of a given tumour cell population. It was
hypothesised that before and after a cytoreductive treatment
a tumour regrows following the same Gompertzian kinetics
(Lloyd, 1975). Based on this assumption a method to quan-
titate the log kill effects induced by the treatment was
developed. This method was applied to analyse our data (see
Matenrals and methods). Owing to the difficulties of measur-
ing the pre- and post-treatment tumour growth kinetics, the
validation of this method in in vivo tumours is problematic.
However, in our work the growth kinetics of treated and
control MTSs could be accurately measured. We therefore
correlated the two parameters ac0 and P for each MTS of
treated non-sterilised MTS with those of control MTSs.
As shown in Figures 6 and 7 the two Gompertzian
parameters ac0 and fi for treated and control mock-treated
MTSs were linearly correlated irrespective of the type of
treatment (r = 0.97 and 0.95 for 136 MCF7 and for 125 9L
spheroids respectively). It thus appears that the Gompertzian
growth of treated MTSs from both cell lines followed the
same pattern as that of the corresponding control MTS
populations. This observation has at least three direct conse-
quences:
1. The ratio o0 P remains unaltered within the log kill
range (0.1-4) observed in our experiments.
2. As a result, the fact that treated non-sterilised and
control MTSs display the same mo0 p ratio (i.e. Gompert-
zian growth kinetics) is a confirmation of the general
validity of the assumptions made to calculate the log
kill effects (see above and Materials and methods).
3. It has been shown (Brunton and Weldon, 1980;
Demicheli et al.. 1989) that a linear correlation between
m0 and P for a given population of MTSs or tumours
implies the existence, for that population, of a
theoretical upper limit of the volume dimensions which
different MTSs or tumours approach following different
Gompertzian curves. This upper limit of volume dimen-
sions for different MTS or tumours is given by (Lloyd.
1975; Brunton and Weldon, 1980; Demicheli et al..
1989):
Vz = V0exp(o0 O
Thus, in our MTS populations of treated MCF7 and 9L
MTSs the final limiting volumes approached the same upper
limits as control MTSs, irrespective of the type of treatment.
That is, when the effects of the IT or toxin treatment were
non-sterilising. the MTSs, following a delay variable in time.
regrew until the volume reached the same maximum value as
control MTSs.
Estimates of the doubling time ofsuriving cells in treated
non-sterilised MTS
The results shown above demonstrate that treated non-
sterilised MTSs and control MTSs approached the same final
n= 136
r2= 0.97
a0 = 9.74 + 0.262
.
0
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P (days-1)
Fire 6 Comparison of Gompertzian parameters estimated in
treated and control MCF7 MTSs. The instantaneous growth rate
of treated and control MTSs was calculated for each spheroid
as described in Materials and methods. The retarding factor P for
each spheroid was instead estimated by fitting of experimental
data of spheroid growth with the Gompertz equation. Each data
point in the figure represents the zm P ratio for a given MTS of
the control (open symbols) or of the treated (closed symbols)
MTS populations; symbols refer to treatment with Tfn-RTA
(circles). OKT9-RTA (squares). Tfn-CRM107 (diamonds) and
ricin (triangles). The result of the linear regression analysis
through the indicated number 'n' of cE0, calculations is reported
in the figure.
cc 2 'a
n= 125
r2 =0.95
ao = 10.720 + 0.261
0.00 0.05 0.10 0.15 0.20
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0.25 0.30
Figure 7 Companrson of Gompertzian parameters estimated in
treated and control 9L MTSs. For explanations see the legend to
Figure 6. In this figure the symbols are as follows: Tfn-RTA
(circles). 0X26-RTA (squares). ricin (triangles).
limiting volumes (Vj. However, the linear relationship
found between ao and P (see Figures 6 and 7). though essen-
tial for predicting the final limiting volumes of different
growing MTS populations, does not give sufficient inform-
ation on the kinetics followed by individual MTS to reach
that upper limit. Elucidation of the post-treatment growth
kinetics of individual MTSs may help in identifying possible
causes leading to the heterogeneous response of MTSs to IT.
The proliferative potential of cells forming the treated MTS
is likely to be an important factor in determining the out-
come of the IT therapy of three-dimensional micromasses.
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We therefore considered the doubling time (TD) as a marker
of the proliferative potential of surviving cells.
Information on MTS growth below V_ can be obtained by
applying the following formula correlating the fraction of
surviving cells F (see also Materials and methods) with the
Igrowth delay'. GD (i.e. the time during which a treated
MTS does not show a measurable regrowth; see also Figure
1) measured for the treated non-sterilised MTS. The result of
this correlation is the doubling time TD of the surviving cells
(Twentyman, 1980): (GD) log 2
TD =
-log (F)
The above equation is valid if the doubling time of regrow-
mg cells in the treated non-stenlised MTS remains constant
(i.e. exponential growth). This constraint applies to our data
because MTSs were treated below the critical volume at
which the transition between the exponential and the
Gompertzian growth is expected to occur. According to
Demicheli et al. (1989). this critical volume can be calculated
on the basis of the linear correlation between ao and f and
turned out to be 16.9 x 10- mm" and 45.4 x 10-3 mm" for
MCF7 and 9L MTS respectively.
We therefore plotted the measured growth delay vs - log
(surviving fraction). and the results are shown in Figures 8
and 9 for MCF7 and 9L MTSs respectively. In both cases.
lines obtained using the above equation have been drawn to
show where points would be expected to lie if the doubling
time of surviving cells in regrowing MTS were as indicated.
As can be seen in Figures 8 and 9, a good correlation
between growth delay and surviving fraction was obtained
for treatments of MTSs with different anti-TfnR ITs and
ricin toxin. The estimated doubling time of the surviving cells
in MCF7 and 9L MTSs ranged between 15 and 50 h. Inter-
estingly. MTSs with the same values of the surviving fraction
of cells escaping treatment had different doubling times (see.
for example Figure 9 for F= 1O-'. TD = 15, 19. 24 and 36 h).
As a consequence. treated non-sterilised MTSs regrew follow-
ing individual growth patterns until their volumes app-
roached ',.
In addition. from Figures 8 and 9. a clear-cut pattern of
behaviour could be discerned (see boxed-in areas): MTSs in
which IT treatment resulted in a considerable cell death
regrew with short TD (for F<0.02 TD+ s.d. = 24.11 ± 5.78 h
and 15.44 ± 2.82 h for MCF7 and 9L MTS respectively):
converselv, when IT treatment had a smaller effect, TD was
somewhat longer (for 0.02 <F< 1 TD ± s.d. = 45.45 ± 14.68
h and 24.05 ± 7.07 h for MCF7 and 9L MTS respec-
tively).
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Figure 8 Plot of MTS growth delay vs cell survival (MCF7
cells). The surviving fraction of cells for each MTS was estimated
based on the Gompertz growth model as described in Materials
and methods. Points represent individual MTSs for which the log
kill could be calculated (see Figure 4) following treatment with
Tfn-RTA (0). OKT9-RTA (0). Tfn-CRM107 (O) and nicin
toxin (A). The lines show where points would be expected to lie
if the doubling time of the surviving cells were as indicated (see
text for details).
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Discussion
The present study demonstrates that: (1) the individual res-
ponse of tumour micromasses to IT treatment can be inves-
tigated and quantitated in vitro in MTSs by applying the
Gompertz growth model and (2) this approach highlights the
extreme variability of response of tumour micromasses to IT
treatment. We have analysed our data by taking advantage
of the Gompertz growth model which allows one to obtain
(1) a rigorous statistical quality control of experimental data.
(2) two biologically meaningful parameters (oE0 and P), (3) a
quantitative evaluation of the growth kinetics of treated
MTSs as compared with control MTSs and (4) a quantitative
determination of the surviving fraction following a given
treatment.
In our work the surviving fraction was calculated in a way
that does not alter the three-dimensional organisation of the
micromasses under study. More conventional ways of
measuring the surviving fraction rely instead on mechanical
enzymatic disaggregation followed by clonogenic assays
(examples in Twentyman, 1980; Rofstad and Sutherland,
1989: Kikuchi et al., 1992). Using this method, however, the
surviving fraction could be greatly underestimated owing to
the cell-damaging effect of the disaggregation procedure
(Twentyman. 1980). Moreover, in clonogenic assays the role
Fire 9 Plot of MTS growth delay *s cell survival (9L cells).
For explanations see the legend to Figure 8. In this figure the
symbols are as follows: Tfn-RTA (0). OX26-RTA (0). ncin
toxin (A).
played by the three-dimensional organisation of tumour cells
on the post-treatment growing potential of the tumour mic-
romasses cannot be evaluated.
Alternative ways of evaluating the effects induced by a
treatment on three-dimensional tumour cell aggregates also
include the measurement of the 'growth delay'. However, the
evaluation of IT cytoreductive effects on the basis of the
'growth delay' only could be misleading. In fact, the 'growth
delay' is strictly dependent on the individual post-treatment
regrowth kinetics ofeach MTS. That is, if a spheroid regrows
slowly, its 'growth delay' will appear longer than that of
another spheroid which has a faster regrowth but whose cell
number has been reduced to the same extent by the treat-
ment. On the other hand, calculations of log kill based on
the Gompertz growth model are acceptable because the
assumptions listed in Material and methods are valid in our
experimental set-up. We believe that this is indeed the case
because the ITs are endowed with biological and phar-Heteogenity ofMTS response toimmunotoxins
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macological properties satisfying those assumptions: in par-
ticular ITs (1) kill cells following first-order kinetics and (2)
exert their cytotoxic effects very rapidly (few hours) com-
pared with the whole post-treatment growth kinetics of the
MTSs (days).
Our results show that the individual response of tumour
micromasses to anti TfnR-IT and to ricin toxin is extremely
heterogeneous. Whereas it is not surprising to observe con-
siderable differences in sensitivity to IT between monolayers
and MTSs (Chignola et al.. 1994b), it was rather unexpected
to find such large differences among tumour micromasses
obtained with the same cell line and treated at the same IT
concentrations. We ruled out the possibility that the
heterogeneity in response to treatment of individual MTSs
could be due to uncertainties in the Gompertzian analysis. In
fact:
1. An analogous degree of heterogeneity was found when
experimental data on the growth delay induced by the
treatments were considered. Values of the growth delay
can be extrapolated from Figures 8 and 9. For both
MCF7 and 9L MTSs the growth delay was highly
heterogeneous. varying between 0 days and 8.0 days.
2. The surviving fraction of cells calculated with the
Gompertzian method, when plotted against the growth
delay (Figures 8 and 9). provided results which are in
agreement with theoretical predictions and paralleling
findings obtained with independent analytical methods
reported by other investigators (Twentyman, 1980).
3. Also, the 'all or nothing' effect shown by IT or toxin at
given concentrations (see. for example, Figure 2c) can
be qualitatively appreciated. Therefore, the
heterogeneous response of MTSs to IT treatment
appears to be the consequence of biological differences
between individual MTSs.
The heterogeneity of response to treatment of individual
MISs might be due to several factors probably acting in
concert (e.g. extracellular matrix composition, permeability
and retention kinetics of IT molecules within individual
MTSs, etc.). which will be investigated in future studies.
Nonetheless. at least some factors could be demonstrated not
to be of relevance in our model on the basis of the following
results:
1. The heterogeneous response of MTSs to ricin treatment
rules out inhomogeneous or insufficient expression of
target antigens as a cause of low sensitivity. In fact.
ricin binds galactose and ,-acetylgalactosamine residues
present in very high numbers at the cell surface (Nichol-
son and Blaustein. 1972: Olsnes and Pihl. 1982). We
cannot however, exclude the possibility that in other
instances heterogeneous expression of target antigen
may result in widely differing effects on three-
dimensional structures.
2. Heterogeneity can be observed with both MCF7 and 9L
MISs treated with anti TfnR-IT; MCF7 (sensitive) and
9L (resistant) cells were used because they show two
distinct patterns of sensitivity to anti TfnR-IT (Chignola
et al.. 1994b). Thus. intrinsic sensitivity of the target
cells to the pharmacological agents used in our assays
does not explain the wide range of cytoreductive effects
observed by us in MISs of both cell lineis.
The results in Figures 8 and 9 indicate that. although
treated non-sterilised MTSs and control MTSs reach the
same final limiting volumes, treated MTSs approach this
upper limit following different individual growth patterns. In
fact, for the same surviving fraction of cells, a wide range of
doubling times could be estimated. Growth kinetics
heterogeneities have been found to affect chemotherapy
(Norton, 1985). Moreover, we have recently found that the
IT cytoreductive effects may be heavily influenced by the
proliferative potential of the target cells (Chignola et al.,
1994a). The results shown in the present report suggest that
this might indeed be the case for MTSs treated with anti-
TfnR IT and with ricin toxin. The scatter of post-treatment
growth kinetics parameters (epitomised by the heterogeneity
of TD values in surviving MTSs) indicates that (1) different
MTSs are composed of different numbers of IT-resistant
cells. which regrow after treatment following variable
kinetics, or (2) the IT treatment facilitates the escape of cell
populations endowed with different growing potential. Fur-
ther efforts in elucidating the relationship between cell sub-
populations within individual tumour masses and sensitivity
to IT treatment are therefore warranted the better to evaluate
the IT anti-tumour potential.
To our knowledge. the cytoreductive effects brought about
in MTS cultures by other therapeutic agents do not result in
such heterogeneous effects. although occasionally variable log
kill effects are reported for radiation and chemotherapeutic
agents (examples in Twentyman. 1980; Sutherland. 1988:
Walker et al.. 1988: Rofstad and Sutherland. 1989: Kikuchi
et al.. 1992). The higher heterogeneity observed with IT may
be explained in terms of the more physiological conditions
used in our assays to estimate the log kill or with the
macromolecular nature of our reagents.
Our study was designed to investigate the effects of IT
treatments on three-dimensional tumour structures sharing
many characteristics with tumour micrometastases in vivo
(Sutherland. 1988). We show that at suboptimal concentra-
tions the cytoreductive effects of the IT are unpredictably
heterogeneous. We also show that treated non-sterilised
MTSs regrow until their volume reaches the same upper
volume as control MTSs. demonstrating that non-sterilising
treatments do not result in a stable reduction of the tumour
cell burden. This may have important consequences for the
therapeutic use of IT in vivo. effective IT concentrations at
the site of the tumour. or within it. being reduced by a
combination of systemic and local factors. It must be con-
sidered. however, that even at suboptimal IT concentrations
we could obtain substantial cv-toreduction in many instances.
In our experiments only one treatment schedule was inves-
tigated (one round. 24 h treatment). We cannot rule out the
possibility that other more complex schedules (e.g. several
rounds, longer treatments) could have resulted in less
heterogeneous effects or in greater cytoreduction. The MTS
model may be helpful in the future for optimising the condi-
tions required to achieve greater IT potency against solid
tumour structures.
Abbreviations IT. immunotoxin: MTS. multicellular tumour
spheroid: RTA. ricin toxin A chain: CRM107. diphtheria toxin
mutant: Tfn. transfemrn: TfnR. transfemrn receptor: HSA-Mo.
thioether-based conjugate between monensin and human serum
albumin: FBS. fetal bovine serum: PBS. phosphate-buffered saline:
BSA. bovine serum albumin.
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